Janux Therapeutics’ (JANX) “Outperform” Rating Reaffirmed at William Blair

Janux Therapeutics (NASDAQ:JANX)‘s stock had its “outperform” rating reiterated by investment analysts at William Blair in a research report issued on Thursday,RTT News reports. William Blair also issued estimates for Janux Therapeutics’ Q4 2024 earnings at ($0.35) EPS, FY2024 earnings at ($1.28) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.45) EPS, FY2026 earnings at ($1.74) EPS and FY2027 earnings at ($2.84) EPS.

JANX has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and set a $63.00 target price on shares of Janux Therapeutics in a research note on Thursday, November 7th. Wedbush reissued an “outperform” rating and issued a $74.00 price objective on shares of Janux Therapeutics in a research note on Thursday, August 8th. Stifel Nicolaus initiated coverage on shares of Janux Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $70.00 price objective for the company. Scotiabank dropped their price objective on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a research note on Friday, August 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $100.00 price objective on shares of Janux Therapeutics in a research note on Thursday, November 7th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $66.44.

Janux Therapeutics Stock Performance

Shares of NASDAQ JANX traded down $0.89 during midday trading on Thursday, reaching $51.10. The stock had a trading volume of 395,034 shares, compared to its average volume of 711,352. The stock has a 50-day moving average of $49.46 and a 200-day moving average of $46.47. The company has a market capitalization of $2.68 billion, a price-to-earnings ratio of -43.67 and a beta of 3.52. Janux Therapeutics has a 12-month low of $7.79 and a 12-month high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The company had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The firm’s revenue for the quarter was down 82.6% compared to the same quarter last year. As a group, analysts forecast that Janux Therapeutics will post -1.34 EPS for the current fiscal year.

Insider Activity

In other news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of Janux Therapeutics stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $42.00, for a total value of $4,551,330.00. Following the transaction, the insider now owns 3,162,851 shares of the company’s stock, valued at $132,839,742. The trade was a 3.31 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Andrew Hollman Meyer sold 50,000 shares of Janux Therapeutics stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $45.96, for a total transaction of $2,298,000.00. Following the completion of the transaction, the insider now directly owns 67,592 shares in the company, valued at approximately $3,106,528.32. The trade was a 42.52 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 420,610 shares of company stock worth $19,288,666. 29.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Janux Therapeutics

Several large investors have recently bought and sold shares of the stock. Ally Bridge Group NY LLC purchased a new stake in Janux Therapeutics during the 3rd quarter worth approximately $4,943,000. FMR LLC grew its position in Janux Therapeutics by 0.6% during the 3rd quarter. FMR LLC now owns 7,824,675 shares of the company’s stock worth $355,475,000 after purchasing an additional 47,075 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Janux Therapeutics by 27.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 30,595 shares of the company’s stock worth $1,390,000 after purchasing an additional 6,547 shares during the last quarter. Algert Global LLC purchased a new stake in Janux Therapeutics during the 3rd quarter worth approximately $1,112,000. Finally, Charles Schwab Investment Management Inc. grew its position in Janux Therapeutics by 202.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock worth $10,639,000 after purchasing an additional 156,675 shares during the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.